NEXTGEN HEALTHCARE, INC (NXGN)
(Delayed Data from NSDQ)
$19.75 USD
+0.51 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.75 USD
+0.51 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Olink Holding AB (publ) Sponsored ADR (OLK) delivered earnings and revenue surprises of 8.33% and 0.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 225% and 3.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Definitive Healthcare Corp. (DH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Definitive Healthcare Corp. (DH) delivered earnings and revenue surprises of 20% and 2.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
NextGen's (NXGN) Behavioral Health Suite Adopted by Mindful Care
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to facilitate Mindful Care's ability to offer same-day appointments via online scheduling.
Here's Why You Should Retain NextGen (NXGN) Stock for Now
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
NextGen's (NXGN) New Cloud-Based Solution to Improve Workflow
by Zacks Equity Research
NextGen's (NXGN) latest product is expected to simplify connectivity for healthcare providers, thereby solving clinical data exchange challenges.
Here's Why You Should Retain NextGen (NXGN) Stock for Now
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
NextGen (NXGN) Riding on the Success of Cloud-Based Solution
by Zacks Equity Research
NextGen's (NXGN) cloud-based healthcare technology solutions boost the company's prospect. Strong adoption of its services continues to boost revenues.
NextGen (NXGN) Behavioral Health Suite Adopted by Compass Health
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to aid Compass Health in improving its workflow.
Nextgen Healthcare (NXGN) Up 2.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nextgen Healthcare (NXGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
Syneos Health (SYNH) Signs New Partnership With Cryoport
by Zacks Equity Research
Syneos Health (SYNH) inks a partnership with Cryoport to deliver seamless integration and insights for key services for cell and gene trial operations to biopharmaceutical customers.
NextGen (NXGN) Q3 Earnings Fall Shy of Estimates, Revenues Top
by Zacks Equity Research
NextGen's (NXGN) third-quarter fiscal 2023 results reflect strength in its Recurring revenues.
Nextgen Healthcare (NXGN) Q3 Earnings Miss Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of -3.70% and 1.08%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Nextgen Healthcare (NXGN) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Nextgen Healthcare (NXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Info Systems Stocks Braving Industry-wide Headwinds
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like 10x Genomics (TXG), NextGen Healthcare (NXGN) and Health Catalyst (HCAT) are expected to gain as COVID-19 severity fades.
Here's Why You Should Retain NextGen (NXGN) Stock for Now
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
NextGen (NXGN) Buys TSI Healthcare to Boost Ambulatory Services
by Zacks Equity Research
NextGen (NXGN) acquires TSI Healthcare which may further solidify NXGN's position in the ambulatory healthcare space.
NextGen Healthcare (NXGN) Q2 Earnings Beat, FY23 View Up
by Zacks Equity Research
NextGen's (NXGN) second-quarter fiscal 2023 results reflect strength in both its revenue sources.
Nextgen Healthcare (NXGN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 4.17% and 1.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
NextGen's (NXGN) Enterprise Adopted by Oak Orchard Health
by Zacks Equity Research
NextGen's (NXGN) EHR and PM solution is expected to aid Oak Orchard Health in improving its workflow.
3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and solid prospects in the RCM space raise optimism about the stock.
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen's (NXGN) solid product portfolio and continued demand for its solutions raise optimism about the stock.
NextGen Healthcare (NXGN) Beats on Q1 Earnings, Cuts FY23 View
by Zacks Equity Research
NextGen Healthcare's (NXGN) first-quarter fiscal 2023 results reflect strength in its Recurring revenues.
Nextgen Healthcare (NXGN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 6.67% and 0.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?